Powered by

Genmab reports USD75m sales milestone in DARZALEX under collaboration with Janssen

Jan 09, 2019 - Global Banking News

Genmab A/S (CPH:GEN), a biotechnology company specialising in the creation and development of differentiated antibody therapeutics for the treatment of cancer, announced on Tuesday the achievement of a USD75m sales volume milestone in its DARZALEX (daratumumab) collaboration with Janssen Biotech Inc (Janssen).

The company said this milestone was triggered by confirmation by Janssen that sales of DARZALEX reached USD2bn in the calendar year of 2018.

In August 2012, Genmab had granted ...